Efficacy of Adaptogens in Patients With Long COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible efficacy of adjuvant treatment with ADAPT-232 in decreasing the duration of the convalescence, alleviation of fatigue, headache, attention deficit, difficult and rapid respiration, depression, anxiety and other symptoms of Long COVID-19 during rehabilitation period.
Epistemonikos ID: c6aab153d3eae4a694fce6e8a3bdcb775e853f9f
First added on: Mar 13, 2021